6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy.
adalimumab
inflammatory bowel disease
infliximab
therapeutic drug monitoring
thiopurines
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
received:
10
04
2024
accepted:
31
07
2024
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
5
9
2024
Statut:
aheadofprint
Résumé
Thiopurine co-therapy with anti-tumour necrosis factor-alpha (anti-TNFα) agents is associated with higher anti-TNFα drug levels and reduced immunogenicity in inflammatory bowel disease (IBD). We aimed to evaluate the association between 6-thioguanine nucleotide (6-TGN) and anti-TNFα levels and the optimal 6-TGN threshold level associated with higher anti-TNFα levels in combination therapy. We performed a retrospective cross-sectional multicentre study of patients with IBD on combination anti-TNFα and thiopurine maintenance therapy between January 2015 and August 2021. Primary outcomes were infliximab and adalimumab levels. Secondary outcomes were antibodies to infliximab (ATI) or adalimumab (ATA). Univariable and multivariable linear regression were performed to identify variables associated with anti-TNFα levels. Receiver operator characteristic curves were used to define the optimal 6-TGN cut-off levels associated with therapeutic anti-TNFα levels. The study included 743 paired 6-TGN and anti-TNFα levels (640 infliximab and 103 adalimumab). 6-TGN levels were associated with infliximab levels, but not adalimumab levels, on univariable and multivariable regression. The optimal 6-TGN cut-off associated with therapeutic infliximab levels (≥5 mcg/mL) was 261 pmol/8 × 10 6-TGN levels were weakly associated with infliximab but not adalimumab levels in combination therapy. 6-TGN levels in the lower end of the therapeutic range (230-260 pmol/8 × 10
Sections du résumé
BACKGROUND
BACKGROUND
Thiopurine co-therapy with anti-tumour necrosis factor-alpha (anti-TNFα) agents is associated with higher anti-TNFα drug levels and reduced immunogenicity in inflammatory bowel disease (IBD).
AIMS
OBJECTIVE
We aimed to evaluate the association between 6-thioguanine nucleotide (6-TGN) and anti-TNFα levels and the optimal 6-TGN threshold level associated with higher anti-TNFα levels in combination therapy.
METHODS
METHODS
We performed a retrospective cross-sectional multicentre study of patients with IBD on combination anti-TNFα and thiopurine maintenance therapy between January 2015 and August 2021. Primary outcomes were infliximab and adalimumab levels. Secondary outcomes were antibodies to infliximab (ATI) or adalimumab (ATA). Univariable and multivariable linear regression were performed to identify variables associated with anti-TNFα levels. Receiver operator characteristic curves were used to define the optimal 6-TGN cut-off levels associated with therapeutic anti-TNFα levels.
RESULTS
RESULTS
The study included 743 paired 6-TGN and anti-TNFα levels (640 infliximab and 103 adalimumab). 6-TGN levels were associated with infliximab levels, but not adalimumab levels, on univariable and multivariable regression. The optimal 6-TGN cut-off associated with therapeutic infliximab levels (≥5 mcg/mL) was 261 pmol/8 × 10
CONCLUSION
CONCLUSIONS
6-TGN levels were weakly associated with infliximab but not adalimumab levels in combination therapy. 6-TGN levels in the lower end of the therapeutic range (230-260 pmol/8 × 10
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Royal Australasian College of Physicians.
Références
Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical management. Aliment Pharmacol Ther 2016; 43: 30–51.
Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis. Clin Gastroenterol Hepatol 2019; 17: 1525–1532.e1.
Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis. Aliment Pharmacol Ther 2015; 41: 734–746.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383–1395.
Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392–400.e3.
Chalhoub JM, Rimmani HH, Gumaste VV, Sharara AI. Systematic review and meta‐analysis: adalimumab monotherapy versus combination therapy with Immunomodulators for induction and maintenance of remission and response in patients with Crohn's disease. Inflamm Bowel Dis 2017; 23: 1316–1327.
Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin‐Biroulet L, Eichner SF et al. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther 2017; 45: 50–62.
Cosnes J, Sokol H, Bourrier A, Nion‐Larmurier I, Wisniewski A, Landman C et al. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. Aliment Pharmacol Ther 2016; 44: 1102–1113.
Kopylov U, Al‐Taweel T, Yaghoobi M, Nauche B, Bitton A, Lakatos PL et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta‐analysis. J Crohns Colitis 2014; 8: 1632–1641.
Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N et al. Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial. J Crohns Colitis 2016; 10: 1259–1266.
Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA et al. Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease‐related complications. J Crohns Colitis 2020; 14: 1354–1363.
Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray‐Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 2018; 155: 337–346.e10.
Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger CM et al. Effectiveness and safety of Immunomodulators with anti‐tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol 2015; 13: 1293–1301.e5; quiz e70, e72.
Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929–936.
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617–1625.
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017; 318: 1679–1686.
Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143: 390–399.e1.
Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014; 146: 941–949.
Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti‐tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta‐analysis. Clin Gastroenterol Hepatol 2009; 7: 874–881.
Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A et al. Concentrations of 6‐thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015; 13: 1118–1124.e3.
Feuerstein JD, Nguyen GC, Kupfer SS, Falck‐Ytter Y, Singh S. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology 2017; 153: 827–834.
Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial. Aliment Pharmacol Ther 2017; 46: 142–149.
Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S et al. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther 2017; 46: 150–161.
van Schaik T, Maljaars JP, Roopram RK, Verwey MH, Ipenburg N, Hardwick JC et al. Influence of combination therapy with immune modulators on anti‐TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis 2014; 20: 2292–2298.
Luber RP, Dawson L, Munari S, Kariyawasam VC, Martin C, Gibson PR et al. Thiopurines and their optimization during infliximab induction and maintenance: a retrospective study in Crohn's disease. J Gastroenterol Hepatol 2021; 36: 990–998.
Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C. A role for Thiopurine metabolites in the synergism between thiopurines and infliximab in inflammatory bowel disease. J Crohns Colitis 2017; 12: 298–305.
Ungaro RC, Colombel J‐F, Dubinsky MC, Jain A, Dervieux T. Impact of thiopurine exposure on immunogenicity to infliximab is negligible in the setting of elevated infliximab concentrations. Inflamm Bowel Dis 2021; 28: 649–651.
Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N et al. Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther 2017; 46: 873–882.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ et al. Predictors of anti‐TNF treatment failure in anti‐TNF‐naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019; 4: 341–353.
Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab‐to‐adalimumab switchers with IBD. Inflamm Bowel Dis 2014; 20: 1714–1721.
Mahmoud R, Schultheiss H‐P, Louwers J, van der Kaaij M, van Hellemondt B, Mahmmod N et al. Immunomodulator withdrawal from anti‐TNF therapy is not associated with loss of response in inflammatory bowel disease. Clin Gastroenterol Hepatol 2022; 20: 2577–2587.e6.
Chupin A, Perduca V, Meyer A, Bellanger C, Carbonnel F, Dong C. Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020; 52: 1289–1297.
Abbas AM, Almukhtar RM, Loftus EV Jr, Lichtenstein GR, Khan N. Risk of melanoma and non‐melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol 2014; 109: 1781–1793.
Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti‐TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014; 23: 735–744.
Zheng KYC, Guo CG, Wong IOL, Chen L, Chung HY, Cheung KS et al. Risk of malignancies in patients with inflammatory bowel disease who used thiopurines as compared with other indications: a territory‐wide study. Therap Adv Gastroenterol 2020; 13: 1756284820967275.
Na R, Laaksonen MA, Grulich AE, Meagher NS, McCaughan GW, Keogh AM et al. Iatrogenic immunosuppression and risk of non‐Hodgkin lymphoma in solid organ transplantation: a population‐based cohort study in Australia. Br J Haematol 2016; 174: 550–562.
Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987; 41: 18–25.
Hagen JW, Pugliano‐Mauro MA. Nonmelanoma skin cancer risk in patients with inflammatory bowel disease undergoing Thiopurine therapy: a systematic review of the literature. Dermatol Surg 2018; 44: 469–480.